The association of ITGBL1 with ECM remodeling and immune evasion has been reported in ovarian and colorectal cancers (31, 32), whereas PI16 has been implicated in fibrotic diseases and the activation of tumor-associated fibroblasts (33). Here, ITGBL1 is linked to neoplasm.